Adjuvant therapy in pancreatic cancer

World Journal of Gastroenterology

Volumn 7, Issue 4, 2001, Pages 482-489

  Ghaneh, P ^a   Slavin, J ^a   Sutton, R ^a   Hartley, M ^a   Neoptolemos, J P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; SPARFOSIC ACID; STREPTOZOCIN; VINCRISTINE;

ADVANCED CANCER; ARTERIOSCLEROSIS; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG MECHANISM; DRUG TOLERABILITY; GASTRODUODENAL ULCER; HUMAN; LIVER DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZATION; REVIEW; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0034893409     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i4.482     Document Type: Review

References (90)

1. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units
2. Incidence treatment and survival in 13, 560 patients with pancreatic cancer: An epidemiological study in the West Midlands
3. Population based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defence Hospitals 1989 - 1994
4. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality
5. One hundred forty five consecutive pancreaticoduodenectomies without mortality
6. Pancreatoduodenectomy for cancer of the head of the pancreas in 201 patients
7. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head
8. Long term survival after resection for ductal adenocarcinoma of the pancreas. It is really improving?
9. Results of extensive surgery for pancreatic carcinoma
10. Survival after resection for ductal adenocarcinoma of the pancreas
11. Pancreatic invasion as the prognostic indicator of duodenal adenocarcinoma reated by pancreatoduodenectomy plus extended lymphadenectomy
12. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging
13. Surgically curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas
14. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy. In the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy study group
15. Standard Kausch-Whipple pancreatoduodenectomy
16. Pylorus preserving pancreaticoduodenectomy versus conventional Whipple operation
17. Adjuvant therapy of resected adenocarcinoma of the pancreas
18. Recurrence of exocrine pancreatic cancer-local or hepatic?
19. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer
20. Recurrence after resection for ductal adenocarcinoma of the pancreas
21. Patterns of failure after curative resection of pancreatic carcinoma
22. The time of occurrence of liver metastasis in carcinoma of the pancreas
23. A clinical study on lymphatic flow in carcinoma of the pancreatic head area-peripancreatic regional lymph node grouping
24. Prediction of resectability of pancreatic malignancy by computed tomography
25. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer
26. Pancreas cancer resection outcome in American university centers in 1989 - 1990
27. Pancreatic cancer treatment in the United States Veteran from 1987 - 1991 - Effect of tumour stage on survival
28. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas
29. Prognostic factors for survival after pancreaticduodenectomy for patients with carcinoma of the pancreatic head region
30. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy
31. Review article: Current treatment and optimal patient management in pancreatic cancer
32. PALA plus 5-fluorouracil (5-FU) and low dose leucovorin (LDLV) in advanced gastric and pancreatic cancer: A phase II trial
33. Combination fluorouracil, folinic acid and interferon alpha-2a: An active regimen in advanced pancreatic carcinoma
34. A randomised trial of gemcitabine versus 5-FU as first line therapy in advanced pancreatic cancer
35. Severe non-haematological toxicity after treatment with gemcitabine
36. Chemotherapy in pancreatic cancer: Results of a controlled prospective randomised, multicentre trial
37. A phase III trial on the therapy of advanced pancreatic cancer
38. Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the veterans administration surgical adjuvant cancer chemotherapy study group
39. Chemotherapy prolongs survival in operable pancreatic carcinoma
40. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
41. Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomised pilot study
42. Surgical treatment of pancreatic cancer: The United States experience
43. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - Results of a controlled, prospective, randomised multicentre study
44. Results of resection for cancer of the exocrine pancreas: A study from the French Association of Surgery
45. External beam plus intra-operative irradiation for gastrointestinal cancers
46. Radiation therapy for pancreatic cancer - A retrospective study of the University of Louisville experience
47. High dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas: A preliminary report of a multiinstitutional trial (radiation therapy oncology group protocol 8801)
48. Intraoperative and external beam irradiation ± 5FU for locally advanced pancreatic cancer
49. High dose preoperative external beam and intraoperative irradiation foe locally advanced pancreatic cancer
50. Intraoperative radiation therapy of pancreatic cancer
51. Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy correlations of a clinical trial
52. Intraoperative and postoperative radiotherapy in pancreatic cancer
53. Adjuvant radiation therapy for pancreatic cancer: A 15 year experience
54. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer
55. Results of surgery and adjuvant radiotherapy for pancreatic cancer
56. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group
57. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
58. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas
59. Extended radical resection of cancer of the pancreas with intraoperative radiotherapy
60. Effectiveness of multimodality treatment for resectable pancreatic cancer
61. Intra-arterial chemotherapy with MMC, CDDP and 5-FU for non-resectable pancreatic cancer - A phase II study
62. Regional chemotherapy for inoperable pancreatic carcinoma
63. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas
64. Modern surgical treatment of pancreatic cancer
65. Palliative and adjuvant regional chemotherapy in pancreatic cancer
66. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: Significant reduction in occurrence of liver metastasis
67. Regional treatment of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. First results of a single institution study
68. Is the long term survival rate improved by preoperative irradiation prior to Whipple's procedure for adenocarcinoma of the pancreatic head?
69. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum
70. Preoperative chemoradiation pancreaticoduodenectomy and intraoperative radiation therapy for adenocarcinoma of the pancreatic head
71. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
72. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An eastern cooperative oncology group study
73. Pre-operative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas
74. Pre-operative chemoradiotherapy and surgical resection of locally advanced pancreatic cancer
75. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma
76. Therapy of locally unresectable pancreatic carcinoma: A randomised comparison of high dose (6000 rads) radiation alone, moderate dose radiation (400 rads + 5 - fluorouracil), and high dose radiation + 5-fluorouracil
77. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: Results of a feasibility study
78. A randomised trial of intraoperative radiation therapy (IORT) vs IORT plus chemotherapy (MTX-5FU) for adenocarcinoma of the pancreas
79. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection
80. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
81. Long term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5 year survivors
82. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival: A prospective, single institution experience
83. Adjuvant radiotherapy and follow on chemotherapy in patients with pancreatic cancer: Results of the UK Pancreatic Cancer Study Group (UKPACA - 1)
84. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels
85. Resected pancreatic cancer: Treatment with adjuvant radiotherapy with or without 5-FU treatment results and patterns of failure
86. Combined radiotherapy and chemotherapy (cisplatin and 5-FU) as palliative treatment for localised unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Results of a feasibility study
87. ESPAC-1: A European randomised controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer
88. Survival, quality of life and quality-adjusted survival of patients in the ESPAC-1 trial: A European randomized trial to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer